Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2021-02-09 Major Shareholding Noti…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
The Capital Group bezit 10,03% van de Galapagos aandelen.pdf
Major Shareholding Notification Classification · 99% confidence The document is a formal notification titled 'The Capital Group bezit 10,03% van de Galapagos aandelen' (The Capital Group owns 10.03% of Galapagos shares). It explicitly states that Galapagos NV received a 'kennisgeving van belangrijke deelneming' (notification of major shareholding) from The Capital Group Companies, Inc., detailing that their stake crossed the 10% threshold on January 22, 2021, in compliance with Belgian transparency legislation regarding voting rights. This content directly corresponds to the definition of a Major Shareholding Notification.
2021-02-09 Dutch
6-K Filing
Regulatory Filings
2021-02-09 English
SC 13G/A Filing
Major Shareholding Notification
2021-01-29 English
NICE recommends Jyseleca® ?(filgotinib) on NHS in landmark decision for rheumatoid arthritis
Regulatory Filings Classification · 95% confidence The document is a press release dated January 21, 2021, announcing that NICE has issued a final appraisal determination (FAD) recommending the use of Jyseleca (filgotinib) for rheumatoid arthritis (RA) on the NHS in England. This type of announcement, which details a regulatory or health authority decision regarding a drug's availability and provides context, financial implications, and scientific background, is characteristic of a general corporate or regulatory update, often related to product commercialization or clinical progress. It is not a full Annual Report (10-K), an Earnings Release (ER), a Call Transcript (CT), or a formal Investor Presentation (IP). Since it is a specific announcement about a regulatory/health body decision impacting the company's product, and it doesn't fit the specific categories like Director's Dealing (DIRS) or Capital Change (CAP), the most appropriate general category for a significant, non-standard regulatory/commercial update that isn't a core financial report is Regulatory Filings (RNS), as it serves as a broad announcement of material information. However, given the content is a press release announcing a positive NICE recommendation (a significant commercial/regulatory milestone for a drug), it is often classified as a general Regulatory Filing (RNS) or sometimes an Earnings Release (ER) if it were tied to quarterly results, but here it is standalone news. Since RNS is the fallback for miscellaneous regulatory announcements, and this is a press release announcing a key regulatory/market access event, RNS is the best fit among the provided options, as it is not a core financial report itself.
2021-01-21 English
NICE recommends Jyseleca® ?(filgotinib) on NHS in landmark decision for rheumatoid arthritis
Regulatory Filings Classification · 95% confidence The document is a press release dated January 21, 2021, announcing that the National Institute for Health and Care Excellence (NICE) in the UK has recommended the drug Jyseleca (filgotinib) for treating rheumatoid arthritis. This type of announcement, detailing a regulatory or reimbursement decision and providing context on the drug's efficacy and market implications, is characteristic of a general corporate announcement or press release related to product news. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a transcript (CT). Since it is a specific announcement about a key business development (a positive NICE recommendation), it fits best under the general 'Regulatory Filings' (RNS) category as a significant, non-standard filing, or potentially an Investor Presentation (IP) if it were structured as a deck, but given the format, RNS is the most appropriate general category for such news releases that aren't explicitly covered by other codes like DIV or CAP. However, since it is a major announcement about a product's market access/reimbursement status, which is crucial for investors, and it is structured as a press release, RNS (Regulatory Filings/Announcements) serves as the best fit among the provided options for a general corporate news release.
2021-01-21 English
6-K Filing
Regulatory Filings
2021-01-21 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.